Skip To Content
JEWISH. INDEPENDENT. NONPROFIT.
The Schmooze

Celebrating 100 Years of Jonas Salk

Happy birthday Jonas Salk!

Today’s Google Doodle pays tribute to the Jewish inventor of the polio vaccine, born 100 years ago today in New York City. Been a long time since high school science class? Here’s a little refresher:

Who Is Jonas Salk

Jonas Salk 1914, New York City – 1995, San Diego) graduated from New York University with a medical degree in 1939. His parents, Jewish Ashkenazi immigrants with little formal education, were eager to see their children succeed. Salk first worked on developing an influenza vaccination before becoming interested in the polio virus. He developed a vaccination which used dead virus, also known as inactivated polio vaccine (IPV). The field trial for the vaccine was one of the largest of its kind, with over 600,000 schoolchildren injected with the vaccine or a placebo, and a million more serving as “observed” controls. In 1955, the vaccine, which showed 90% effectiveness, was approved to international acclaim. He continued his biomedical research in the Salk Institute for Biological Sciences, which he founded in San Diego, Ca., focusing on multiple sclerosis and HIV.

Image by Wikimedia Commons

About Polio

The polio virus is transmitted through water and faeces, where it can remain infectious for a long period of time, and causes paralysis. Children are especially vulnerable. Today, it’s easy to forget the terror caused by polio epidemics. In 2009, a PBS documentary declared that, “Apart from the atomic bomb, America’s greatest fear was polio.” In the 1950s, between 25,000 and 50,000 new cases of polio were diagnosed every year in the United States alone. When news that Salk’s vaccine testing was successful went public in 1955, he was hailed as a “miracle maker.”) In fact, April 12, 1955 almost became a national holiday . The last U.S. polio case was reported in 1979.

The Vaccine

Salk’s vaccine uses dead polio viruses, grown on monkey kidney and then inactivated with formaldehyde. The main disadvantage of the inactivated polio vaccine (IPV) is that the immunization is not life-long. Albert Sabin, another member of the tribe, developed an oral polio vaccine around the same time, which uses live viruses and digested orally, making it cheaper and easier administrate. Immunization is life-long, but the vaccination carries a small risk of infection, especially in people with compromised immune systems. In 2000, the U.S. government switched back to recommending the use of Salk’s vaccine because the risks associated with Sabin’s oral vaccine, which outweighed the cost benefits.

A message from our CEO & publisher Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism during this critical time.

We’ve set a goal to raise $260,000 by December 31. That’s an ambitious goal, but one that will give us the resources we need to invest in the high quality news, opinion, analysis and cultural coverage that isn’t available anywhere else.

If you feel inspired to make an impact, now is the time to give something back. Join us as a member at your most generous level.

—  Rachel Fishman Feddersen, Publisher and CEO

With your support, we’ll be ready for whatever 2025 brings.

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free, unless it originated with JTA, Haaretz or another publication (as indicated on the article) and as long as you follow our guidelines. You must credit the Forward, retain our pixel and preserve our canonical link in Google search.  See our full guidelines for more information, and this guide for detail about canonical URLs.

To republish, copy the HTML by clicking on the yellow button to the right; it includes our tracking pixel, all paragraph styles and hyperlinks, the author byline and credit to the Forward. It does not include images; to avoid copyright violations, you must add them manually, following our guidelines. Please email us at editorial@forward.com, subject line “republish,” with any questions or to let us know what stories you’re picking up.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.

Exit mobile version